{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.4.9.1 Restricted Therapy and Medications', '76', '9.4.10', 'Treatment Compliance', '78', '9.5', 'Efficacy, Quality-of-Life, Pharmacokinetic, and Safety Variables', '78', '9.5.1', 'Efficacy Variables', '78', '9.5.1.1 Proptosis (Exophthalmos)', '78', '9.5.1.2 Clinical Activity Score (CAS)', '79', '9.5.1.3 Clinical Measures of Severity', '79', '9.5.1.3.1', 'Motility Restriction - Details for Measurement', '80', '9.5.2', 'Quality-of-Life Assessment', '81', '9.5.3', 'Pharmacokinetic Measurements', '81', '9.5.4', 'Biomarker Assessments', '81', '9.5.5', 'Safety Variables', '82', '9.5.5.1', 'Adverse Events', '82', '9.5.5.1.1', 'Definitions', '82', '9.5.5.1.2', 'Documentation of Adverse Events', '84', '9.5.5.1.3', 'Intensity of Adverse Events', '84', '9.5.5.1.4', 'Relationship to Study Drug', '84', '9.5.5.1.5', 'Reporting and Documenting SAEs', '85', '9.5.5.1.6', 'Follow-Up of Adverse Events', '86', '9.5.5.1.7', 'Medication Error and Overdose', '86', '9.5.5.1.8', 'Review of Adverse Events and Emerging New Safety Information', '86', '9.5.5.1.9', 'Reporting of IND Safety Reports', '87', '9.5.5.1.10', 'Reporting of Suspected Unexpected Serious Adverse Reactions in', 'the EU', '87', '9.5.5.1.11 Development Safety Update Reports', '87', '9.5.5.2 Pregnancy Reporting', '87', '9.5.5.3', 'Medical History', '88', '9.5.5.4', 'Vital Signs', '88', '9.5.5.5 Physical and Ophthalmic Examinations, Height, and Weight', '88', '9.5.5.6', 'ECGs', '89', '9.5.5.7 Clinical Laboratory Safety Tests', '89', '9.5.5.8 Immunogenicity Testing', '90', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 35 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '9.5.5.9 Data Safety Monitoring Board', '91', '9.5.6', 'Appropriateness of Measurements', '91', '9.5.7', 'Study Procedures', '91', '9.5.7.1', 'Screening', '91', '9.5.7.2', 'Day 1/Baseline', '93', '9.5.7.3', 'Week 1', '94', '9.5.7.4', 'Week 3', '94', '9.5.7.5', 'Week 4', '95', '9.5.7.6', 'Week 6', '95', '9.5.7.7', 'Week 9', '96', '9.5.7.8', 'Week 12', '96', '9.5.7.9', 'Week 15', '97', '9.5.7.10', 'Week 18', '98', '9.5.7.11 Week 21', '98', '9.5.7.12 Week 24', '99', '9.5.7.13 Week 28', '100', '9.5.7.14 Week 36', '100', '9.5.7.15 Week 48', '100', '9.5.7.16 Week 60', '101', '9.5.7.17 Week 72 (Termination Visit or Premature Withdrawal Visit)', '101', '9.5.7.18 Week 96 - Follow-Up Contact', '102', '9.5.7.19 Week 120 - Follow-Up Contact', '102', '9.6', 'Statistical Methods and Determination of Sample Size', '102', '9.6.1', 'Endpoints', '102', '9.6.1.1', 'Primary Endpoint', '102', '9.6.1.2 Secondary Endpoints (analyzed hierarchically)', '102', '9.6.1.3 Exploratory Endpoints', '102', '9.6.2', 'Populations for Analysis', '103', '9.6.3', 'Primary and Secondary Endpoint Analysis', '103', '9.6.4', 'Exploratory Analyses', '104', '9.6.4.1 harmacokinetics/Pharmacodynamics', '104', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 36 of 117']\n\n###\n\n", "completion": "END"}